IPO
China's Ucommune acquired by US-listed SPAC for $765m
Ucommune, a Chinese co-working space operator that failed to get traction with an attempted New York IPO last year, has been acquired by a US-listed special purpose acquisition company (SPAC) at a valuation of $764.9 million.
PE-backed Hygeia completes $286m Hong Kong IPO
Chinese radiotherapy business Hygeia Healthcare, which counts Warburg Pincus, Boyu Capital, and CITIC Capital among its investors, raised HK$2.22 billion ($286.4 million) in its Hong Kong IPO.
China healthcare IPOs: Good prognosis?
There has been a steady stream of China healthcare IPOs - most of them drug developers - on the domestic, Hong Kong and US bourses in recent months. They might be benefiting from a COVID-19 tailwind but it won't be permanent
China's Agora more than doubles in value after $350m US IPO
Agora.io, a real-time voice and video communication platform established by Tony Zhao, formerly CTO of Chinese social networking player YY.com, saw its stock gain 151% on its NASDAQ trading debut following a $350 million IPO.
VC-backed SinocellTech enjoys strong Star Market debut
Chinese drug developer SinocellTech nearly trebled in value on its first day of trading on China's Science and Technology Innovation Board (Star Market) following a RMB1.28 billion ($181 million) IPO.
Toshiba seeks exit from PE-controlled flash memory business
Toshiba is exploring ways to fully exit its 40.2% stake in Kioxia Holdings, two years after selling control of the Japanese flash memory division to a Bain Capital-led consortium for an enterprise valuation of JPY2 trillion ($18.7 billion).
Chinese IPOs: One less option
Will Chinese companies listed in the US become the latest casualties of tensions between the two countries? It could lead to a narrowing in IPO exit options for PE and VC investors
China's Genetron trades flat after upsizing US IPO
Genetron Holdings, a Chinese company that uses DNA sequencing to support the diagnosis and treatment of cancer, traded flat on its NASDAQ debut following a larger-than-planned $256 million IPO.
China gay dating app Blued pursues US IPO
BlueCity Holdings, the company behind Chinese gay dating platform Blued, has filed an application to list on NASDAQ, which would provide a liquidity event for several PE and VC investors.
India's Happiest Minds Technologies files for IPO
Indian IT outsourcing company Happiest Minds Technologies, which is backed by J.P. Morgan Asset Management, has filed for an initial public offering.
China's Burning Rock soars on debut after $222m US IPO
Burning Rock Biotech, a venture capital-backed, China-based provider of genetic testing services used in cancer diagnosis, rose 49% on its trading debut following a $222.8 million US IPO.
China's Dada Nexus trades flat after $322m US IPO
Dada Nexus, a Chinese last-mile delivery platform backed by the likes of JD.com, Walmart, Sequoia Capital China, and DST Global, traded flat on its NASDAQ debut following a $320 million IPO.
STIC-backed Korean game publisher files for US IPO
DoubleDown Interactive, a STIC Investments-backed Korean online game publisher best known for its flagship casino offering, has filed to list in the US.
PE-backed Chinese pop toy retailer pursues Hong Kong IPO
Pop Mart International Group, China’s largest fashion toy retailer, has filed for a Hong Kong IPO. Sequoia Capital China, Loyal Valley Capital and Huaxing Growth Fund are its three largest institutional backers.
China's Burning Rock Biotech files for US IPO
Burning Rock Biotech, a venture capital-backed, China-based provider of genetic testing services used in cancer diagnosis, has filed for an IPO in the US.
PE-backed Kintor Pharma raises $240m in Hong Kong IPO
Kintor Pharmaceutical, a Chinese drug developer backed by the likes of HighLight Capital and Shenzhen Green Pine Capital Partners, posted a 7% gain on debut following a HK$1.86 billion ($240 million) Hong Kong IPO.
Hong Kong ups disclosure requirements for biotech IPOs
The Hong Kong Stock Exchange has tightened disclosure requirements for companies looking to take advantage of two-year-old reforms permitting listings by pre-revenue biotech companies.
China last-mile delivery platform files for US IPO
Dada Nexus, a Chinese last-mile delivery platform backed by the likes of JD.com, Walmart, Sequoia Capital China, and DST Global, has filed for a US IPO.
Cashlez gains on debut after Indonesia IPO
Indonesian mobile point-of-sale solution provider Cashlez - a portfolio company of Mandiri Venture Capital - traded up on debut following an IDR87.5 billion ($5.7 million) domestic IPO.
China's Kingsoft Cloud files for US IPO
Kingsoft Cloud, China’s largest independent provider of cloud-based IT services, has filed to list in the US. Kingsoft Corporation and Xiaomi, the two largest shareholders, have indicated they will commit $75 million to the offering.
Akeso Biopharma trades up after $333m Hong Kong IPO
Akeso Biopharma, a private equity-backed Chinese drug developer specializing in treatments that use the immune system to fight cancer, saw its stock jump 50% in early trading on the Hong Kong Stock Exchange following a HK$2.58 billion ($333 million) IPO....
HighLight-backed Zentalis raises $165m in US IPO
Zentalis Pharmaceuticals, a US-based cancer drug developer, raised $165.2 million in its NASDAQ IPO, facilitating a liquidity event for Chinese healthcare investment specialist HighLight Capital.
VC-backed Chinese AR start-up raises $26m in US IPO
WiMi Hologram Cloud, a PE-backed Chinese augmented reality (AR) technology developer, traded flat on its opening day on NASDAQ following a $26.1 million IPO.
Deal focus: Carlyle's SBI Cards bet pays out
The Carlyle Group achieved an 8x return through a partial exit via SBI Cards’ IPO. The private equity firm still holds a 16% stake and is a resolute believer in the growth potential of India’s credit card market